Jade Competitors

Stocks . USA . 
Stock . Jade Biosciences,
JBIO Stock   7.19  0.31  4.51%   
Jade Biosciences, competes with Lipocine, Nextplat Corp, Clearmind Medicine, Allegheny Technologies, and Insteel Industries; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Jade Biosciences, competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Jade Biosciences, to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Jade Biosciences, Correlation with its peers.
To learn how to invest in Jade Stock, please use our How to Invest in Jade Biosciences, guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Jade Biosciences, competition on your existing holdings.
  
Build AI portfolio with Jade Stock
As of the 31st of July 2025, Return On Tangible Assets is likely to drop to -1.22. In addition to that, Return On Capital Employed is likely to drop to -1.1. As of the 31st of July 2025, Return On Tangible Assets is likely to drop to -1.22. In addition to that, Debt To Assets is likely to drop to 1.18.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.187.9913.80
Details
Intrinsic
Valuation
LowRealHigh
1.217.0212.83
Details
Naive
Forecast
LowNextHigh
1.126.9312.74
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
6.699.0311.37
Details

Jade Biosciences, Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Jade Biosciences, and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Jade and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Jade Biosciences, does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ALNT
+ 0.95
ATI
KALU
+ 0.92
NXPL
ALNT
+ 0.9
NXPL
KALU
+ 0.9
ALNT
KALU
+ 0.89
ATI
ATI
+ 0.86
NXPL
  
High negative correlations   
KALU
- 0.32
LPCN
NXPL
- 0.3
LPCN
ALNT
- 0.24
LPCN
ATI
- 0.22
LPCN
IIIN
- 0.14
LPCN
ATI
- 0.06
CMND

Risk-Adjusted Indicators

There is a big difference between Jade Stock performing well and Jade Biosciences, Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Jade Biosciences,'s multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Jade Biosciences, Competitive Analysis

The better you understand Jade Biosciences, competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Jade Biosciences,'s competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Jade Biosciences,'s competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
JBIO LPCN NXPL CMND ATI IIIN ALNT KALU
 4.51 
 7.19 
Jade
 3.00 
 3.23 
Lipocine
 4.23 
 0.68 
Nextplat
 1.01 
 1.00 
Clearmind
 18.36 
 76.94 
Allegheny
 0.88 
 36.10 
Insteel
 1.79 
 40.31 
Allient
 0.71 
 77.31 
Kaiser
Market Volatility
(90 Days Market Risk)
Relatively risky
Relatively risky
Abnormally volatile
Extremely Dangerous
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Weak
OK
Weak
Very Strong
Insignificant
Solid
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Quite High
Below Average
Low
Very Small
Very Low
Very Low
Very Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Buy
Strong Buy
Not Available
Not Available
Strong Buy
Hold
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Strong Hold
Strong Buy
Strong Buy
Current Ratio
N/A
22.23 X
15.15 X
0.03 X
2.88 X
5.36 X
N/A
2.41 X
Net Asset
N/A
22.51 M
36.48 M
7.26 M
5.23 B
422.55 M
575.78 M
2.31 B
Profit Margin
N/A
(1.46) %
(0.22) %
N/A
0.09 %
0.05 %
0.02 %
0.02 %
EBITDA
N/A
(1.11 M)
(20.15 M)
(5.85 M)
608.9 M
40.79 M
56.05 M
223.6 M
Current Valuation
379.13 M
(1.9 M)
2.72 M
706.09 K
14.71 B
657.34 M
869.54 M
2.35 B
Operating Margin
N/A
(22.27) %
(0.10) %
N/A
0.13 %
0.11 %
0.08 %
0.04 %
Price To Book
N/A
0.93 X
0.73 X
2.31 X
7.10 X
1.98 X
2.46 X
1.62 X
Retained Earnings
N/A
(199.77 M)
(48.95 M)
(24.02 M)
64.3 M
245.34 M
177.01 M
6.2 M
Current Asset
N/A
29.41 M
N/A
N/A
1.87 B
68.69 M
N/A
501.6 M
Five Year Return
N/A
N/A
N/A
N/A
2.44 %
0.46 %
N/A
2.77 %
Beta
N/A
1.3
0.92
-1.28
1.13
0.67
1.51
1.44
Number Of Employees
30
16
162
N/A
7.8 K
929
2.52 K
3.9 K
Shares Outstanding
32.24 M
5.35 M
25.96 M
5.38 M
141.07 M
19.41 M
16.93 M
16.18 M
Cash Flow From Operations
N/A
(1.22 M)
(5.46 M)
(4.86 M)
407.2 M
58.21 M
41.85 M
167.1 M
Annual Yield
0.28 %
N/A
N/A
N/A
N/A
0 %
0 %
0.04 %
Total Debt
N/A
1.51 M
2.26 M
53.14 K
1.9 B
1.69 M
249.13 M
1.09 B
Return On Equity
N/A
-0.25
-0.63
-1.39
0.25
0.0887
0.0364
0.0758
Number Of Shares Shorted
1.87 M
100.39 K
182.19 K
533.02 K
4.25 M
314.37 K
405.87 K
462.31 K
Book Value Per Share
(14.35) X
3.59 X
0.98 X
0.45 X
13.28 X
18.35 X
16.07 X
48.42 X
Return On Asset
N/A
-0.18
-0.12
-0.52
0.0728
0.0569
0.0291
0.027
Current Liabilities
N/A
1.57 M
N/A
N/A
686.5 M
36.27 M
N/A
169.3 M
Total Asset
N/A
22.51 M
36.48 M
7.26 M
5.23 B
422.55 M
575.78 M
2.31 B
Short Ratio
1.20 X
3.23 X
6.36 X
0.24 X
2.28 X
2.96 X
2.66 X
3.26 X
Target Price
16.67
7.38
N/A
N/A
95.56
39.0
37.33
78.0
Debt To Equity
N/A
0.01 %
0.05 %
N/A
1.84 %
0 %
N/A
1.69 %
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
0.12
0.12
3.08
Shares Owned By Institutions
33.33 %
9.72 %
4.39 %
10.90 %
96.25 %
87.26 %
70.38 %
95.00 %
Market Capitalization
280.13 M
17.82 M
18.43 M
5.33 M
13.29 B
706.9 M
670.38 M
1.26 B
Price To Earning
N/A
15.80 X
N/A
(750.00) X
153.89 X
15.12 X
N/A
297.18 X
Price To Earnings To Growth
N/A
N/A
N/A
N/A
1.20 X
1.02 X
N/A
2.24 X
Price To Sales
N/A
4.85 X
0.29 X
N/A
2.98 X
1.17 X
1.30 X
0.40 X
Net Income
N/A
8.35 K
(23.12 M)
(5.25 M)
382.7 M
19.3 M
13.17 M
46.8 M
Earnings Per Share
N/A
(1.01) X
(0.65) X
(1.12) X
2.76 X
1.59 X
0.58 X
3.32 X
Shares Owned By Insiders
0.03 %
2.95 %
46.65 %
2.79 %
0.98 %
4.96 %
15.13 %
1.77 %
Revenue
N/A
11.2 M
65.48 M
N/A
4.36 B
529.2 M
529.97 M
3.02 B
Working Capital
N/A
20.81 M
23.27 M
2.96 M
1.74 B
220.26 M
180.2 M
575.8 M
Cash And Equivalents
N/A
37.4 M
20.47 M
1.65 K
584 M
48.32 M
N/A
129.3 M
Cash Per Share
N/A
0.42 X
2.15 X
N/A
2.55 X
2.48 X
N/A
8.15 X
Gross Profit
N/A
3.67 M
14.83 M
N/A
951.9 M
77.09 M
161.07 M
347.4 M
Day Typical Price
7.12
3.3
0.69
1.01
80.02
35.77
40.03
76.65
Accumulation Distribution
8833.11
548.92
2058.59
2055.75
1 M
3301.4
5196.59
8630.69
Daily Balance Of Power
0.6889
(0.45)
(0.75)
0.1667
(1.61)
(0.29)
0.4733
(0.22)
Period Momentum Indicator
0.31
(0.10)
(0.03)
0.01
(17.30)
(0.32)
0.71
(0.55)
Rate Of Daily Change
1.05
0.97
0.96
1.01
0.82
0.99
1.02
0.99
Day Median Price
7.09
3.34
0.69
1.01
81.57
35.6
39.89
76.32
Price Action Indicator
0.26
(0.16)
(0.03)
(0.01)
(13.28)
0.34
0.78
0.72
Relative Strength Index
41.47
56.39
52.62
53.11
74.15
48.52
67.54
51.66
Coefficient Of Variation
(734.10)
2801.64
971.3
4096.17
256.25
1061.94
350.04
532.19
Mean Deviation
5.94
2.89
3.73
2.68
1.31
1.32
2.13
1.65
Jensen Alpha
(1.90)
0.189
0.5221
0.184
0.7597
(0)
0.7217
0.1539
Total Risk Alpha
(4.21)
(0.68)
(0.46)
(0.78)
0.4402
(0.19)
0.2998
(0.02)
Sortino Ratio
N/A
(0)
0.0835
(0.01)
0.5966
0.0041
0.4435
0.1302
Downside Variance
N/A
14.7
16.74
14.95
1.53
3.28
3.36
3.91
Standard Deviation
12.7
4.2
4.86
4.51
2.3
1.77
3.4
2.22
Kurtosis
34.82
4.89
1.57
10.2
18.61
2.22
19.35
0.6011
Potential Upside
8.71
6.97
9.59
5.05
3.24
2.79
4.58
4.3
Treynor Ratio
(1.65)
(0.42)
(2.34)
(0.18)
1.03
0.1474
0.5963
0.2397
Maximum Drawdown
88.91
27.06
24.66
32.22
17.43
9.92
24.56
11.22
Variance
161.35
17.65
23.66
20.34
5.29
3.12
11.57
4.91
Market Risk Adjusted Performance
(1.64)
(0.41)
(2.33)
(0.17)
1.04
0.1574
0.6063
0.2497
Risk Adjusted Performance
(0.09)
0.0355
0.0872
0.027
0.3053
0.0777
0.2264
0.1503
Skewness
(4.89)
1.02
0.9008
2.18
3.4
(0.83)
3.43
0.2352
Semi Deviation
N/A
3.58
3.55
3.16
0.2241
1.68
1.12
1.61
Information Ratio
(0.15)
(0)
0.0703
(0.01)
0.3212
0.0042
0.239
0.1162
Value At Risk
(11.99)
(6.18)
(5.71)
(5.26)
(1.48)
(2.16)
(2.89)
(2.87)
Expected Short fall
N/A
(3.22)
(4.89)
(3.65)
(1.74)
(1.48)
(2.57)
(1.84)
Downside Deviation
N/A
3.83
4.09
3.87
1.24
1.81
1.83
1.98
Semi Variance
N/A
12.82
12.61
9.98
0.0502
2.82
1.26
2.59

Jade Biosciences, Competition Performance Charts

Five steps to successful analysis of Jade Biosciences, Competition

Jade Biosciences,'s competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Jade Biosciences, in relation to its competition. Jade Biosciences,'s competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Jade Biosciences, in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Jade Biosciences,'s competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Jade Biosciences,, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Jade Biosciences, position

In addition to having Jade Biosciences, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Jade Biosciences, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jade Biosciences,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jade Biosciences, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jade Biosciences, Stock:
How To Invest In Jade
Details
Is Jade Stock a good investment?
Details
What is Jade Biosciences,'s Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Jade Biosciences, Correlation with its peers.
To learn how to invest in Jade Stock, please use our How to Invest in Jade Biosciences, guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Jade Biosciences,. If investors know Jade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Jade Biosciences, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Jade Biosciences, is measured differently than its book value, which is the value of Jade that is recorded on the company's balance sheet. Investors also form their own opinion of Jade Biosciences,'s value that differs from its market value or its book value, called intrinsic value, which is Jade Biosciences,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Jade Biosciences,'s market value can be influenced by many factors that don't directly affect Jade Biosciences,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Jade Biosciences,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Jade Biosciences, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Jade Biosciences,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY